Outcomes of Endoscopic Sleeve Gastroplasty Following Laparoscopic Adjustable Gastric Band: A Propensity Score-matched Analysis.

Autor:	Maselli DB; True You Weight Loss, Atlanta, GA., Wooley C; True You Weight Loss, Cary, NC., Lee D; True You Weight Loss, Cary, NC., Waseem A; True You Weight Loss, Cary, NC., Donnangelo LL; True You Weight Loss, Atlanta, GA., Secic M; Secic Statistical Consulting Inc, Cleveland, OH., Coan B; True You Weight Loss, Cary, NC., McGowan CE; True You Weight Loss, Cary, NC.
Jazyk:	angličtina
Zdroj:	Surgical laparoscopy, endoscopy & percutaneous techniques [Surg Laparosc Endosc Percutan Tech] 2024 Apr 01; Vol. 34 (2), pp. 185-189. Date of Electronic Publication: 2024 Apr 01.
DOI:	10.1097/SLE.0000000000001265
Abstrakt:	Background: The performance of endoscopic sleeve gastroplasty (ESG) in patients with prior laparoscopic adjustable gastric band (LAGB) has not been characterized. Materials and Methods: This is a retrospective propensity score-matched study of ESG after LAGB at 2 centers with expertise in bariatric endoscopy. The primary outcome was total weight loss (TWL) at 12 months. Secondary outcomes included TWL at 3 and 6 months, 12-month excess weight loss (EWL), procedural characteristics, predictors of TWL, and serious adverse events. Results: Twenty-six adults (88.5% female, age 50.8 y, BMI 36.5 kg/m 2 ) with prior LAGB (median duration 8 y) underwent ESG at a median of 3 years after LAGB removal. A 2:1 age-matched, sex-matched, and BMI-matched comparator group was created, comprising ESG patients from the same organization and time frame but without prior LAGB. TWL for the LAGB-to-ESG cohort versus the ESG-only cohort was 10.1±5.5% versus 13.0±4.4% at 3 months ( P =0.0256), 12.4±7.2% versus 16.0±5.4% at 6 months ( P =0.0375), and 12.7±8.2% versus 18.4±6.5% at 12 months ( P =0.0149). At 12 months, the LAGB-to-ESG cohort had an EWL of 52.5±50.0%, and 75% achieved TWL ≥10%. There was no association between TWL at 3, 6, or 12 months and the following traits: age or BMI at the time of ESG, patient sex, and time from LAGB removal to ESG. No serious adverse events occurred in either cohort. Conclusion: ESG after LAGB facilitates safe and clinically meaningful weight loss but is attenuated compared to primary ESG. Competing Interests: C.E.M.: former consultant for Apollo Endosurgery, and has received honoraria for educational consulting. D.B.M.: consultant for Apollo Endosurgery, and has received honoraria for educational consulting. The remaining authors declare no conflicts of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu